Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paediatric Hepatic International Tumour Trial
NL-OMON59523Phase 3Recruiting
- Sponsor
- University of Birmingham
- Start
- Jul 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine, oxaliplatin, sorafenib, cisplatin, doxorubicin and 5 more in hepatoblastoma and hepatocellular carcinoma (HCC) (13 arms), sponsored by University of Birmingham. Primary endpoints: Event-free survival and Response in hepatocellular carcinoma. Started Jul 2019; status: recruiting.
02
Drugs
gemcitabineoxaliplatinsorafenibcisplatindoxorubicin
03
Conditions
hepatoblastomahepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NL-OMON59523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59523.